BTK Inhibitors in R/R CLL: Navigating Options and Tailoring Treatment

home / peer-exchange / btk-inhibitors-in-r-r-cll-navigating-options-and-tailoring-treatment

Callie Coombs, MD; Matthew Davids, MD, MMSc; Seema Bhat, MD; and Lori Leslie, MD, discuss venetoclax-obinutuzumab therapy, pirtobrutinib’s progression-free survival data from the BRUIN CLL-321 trial at ASH 2024, Bruton tyrosine kinase (BTK) inhibitor safety profiles, cost considerations under the Inflation Reduction Act, and clinical strategies for managing BTK inhibitor toxicity.

Episodes

December 20th 2024EP. 1: Fixed-Duration Options for CLL

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.

January 2nd 2025EP. 2: Pirtobrutinib in the BRUIN CLL-321 Study

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.

January 10th 2025EP. 3: Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.

January 17th 2025EP. 4: Sequencing Considerations in Relapsed/Refractory CLL

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.